In the absence of a submission from the holder of the marketing authorisation, adalimumab (Humira®) cannot be endorsed for use within NHS Wales for the of treatment of moderately active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.